Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058914 | 1.00 | TGFBR1 (0.36) | TGFBR1NFE2L2LMNAHTTGSK3A | |
| SCHEMBL25120559 | 0.81 | GPBAR1 (0.44) | NFE2L2GPBAR1MAPK14CCNE1CDK2 | |
| SCHEMBL30949157 | 0.81 | GPBAR1 (0.44) | NFE2L2GPBAR1MAPK14CCNE1CDK2 | |
| SCHEMBL22167088 | 0.80 | TGFBR1 (0.33) | TGFBR1NFE2L2GPBAR1MAPK14 | |
| SCHEMBL23557303 | 0.78 | ABL1 (0.43) | — | |
| SCHEMBL22167063 | 0.78 | PTGS2 (0.35) | NFE2L2GPBAR1PTGS2 | |
| SCHEMBL25696517 | 0.78 | CDC7 (0.36) | TGFBR1LMNAHTTGSK3AGSK3B | |
| SCHEMBL31058944 | 0.78 | CDC7 (0.36) | TGFBR1LMNAHTTGSK3AGSK3B | |
| SCHEMBL21870524 | 0.77 | NFE2L2 (0.42) | NFE2L2GSK3BCDC7CDK2KMO | |
| Hydrochloric Acid SCHEMBL29263024 | 0.76 | CDC7 (0.36) | TGFBR1LMNAHTTGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11800788-B2 | Organometallic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-11800788-B2 | Organometallic compound and organic light-emitting device including i he same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-10-24 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| WO-2023049369-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-03-30 | — | — | WO | disclosed |
| US-20200212319-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
| EP-3674308-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2020-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11800788-B2 | Organometallic compound and organic light-emitting device including i he same | UBE2L3, CRY1, OR10J3 | TGFBR1 1110/4885NFE2L2 44/4885LMNA 4520/4885 |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | TGFBR1 1280/4885NFE2L2 3701/4885LMNA 287/4885 |
| US-20200212319-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | OR10J3, UBE2L3, NR2E3 | TGFBR1 1314/4885NFE2L2 17/4885LMNA 4643/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | TGFBR1 1280/4885NFE2L2 3701/4885LMNA 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.